A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Ramucirumab (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RELAY
- Sponsors Eli Lilly
- 18 Oct 2017 Results (data cut off: 31 May 2017, n=14) from part A (phase Ib) of the study assessing safety and tolerability, presented at the 18th World Conference on Lung Cancer.
- 02 Sep 2017 Planned End Date changed from 1 Dec 2019 to 1 Aug 2021.
- 13 Jun 2017 Planned End Date changed from 1 Apr 2020 to 1 Dec 2019.